Article
Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 May 2016
Zhang Yan, Wang WeiYa, Wang Yan, Xu Yong, Tian Ye, Huang MeiJuan, Lu You
Abstract excerpt
MMNG HOS Transforming gene (MET) is an important driver gene in non-small cell lung cancer. Yet, MET-relevant biomarkers predictive of clinical response to MET inhibitors remain elusive. Limited studies have indicated some possibly effective biomarkers, including amplification with a high-level MET/centromere probe of chromosome 7 (CEP7) ratio, MET exon 14 (METex14) splicing mutations, and MET overexpression. MET...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.